Hypertension 2008, refining our treatment

Geriatrics

Volumn 63, Issue 10, 2008, Pages 14-20

  Leibovitch, Eric R ^a,b  

^a VENTURA COUNTY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood pressure; Cardiovascular risk; Elderly; Home monitoring; Hypertension; Prehypertension; Resistant hypertension

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL; NEBIVOLOL; THIAZIDE DIURETIC AGENT; TORASEMIDE;

ARTERIAL PRESSURE; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HOME MONITORING; HUMAN; HYPERTENSION; LOW DRUG DOSE; MONOTHERAPY; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AGED; DRUG COMBINATION; REVIEW;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION;

EID: 54049144649     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Prospective Studies Collaboration. Age specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
2. Fagard RH. Does low on-treatment diastolic blood pressure influence prognosis in systolic hypertension patients? Cardiovascular Review. 2008;25:28-31.
3. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898.
4. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double blind, placebo controlled trial. Lancet Neurol. 2008;7:683-689.
5. Pickering TG, Miller NH, Ogedegbe G, et al. Call to action and reimbursement for home blood pressure monitoring: A joint scientific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension. 2008;52:1-9.
6. Mancia G, Facchetti R, Bombelli M, et al. Long term risk of mortality associated with selective and combined elevation in office, home and ambulatory blood pressure. Hypertension. 2006;47:846-853.
7. Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of "Masked Hyertension" detected by blood pressure self measurement in elderly treated hypertensive patients. JAMA. 2004;291(11):1342-1349.
8. Padfield PL, Parati G. Home blood pressure monitoring in clinical practice: how many measurements and when? J Hypertens. 2007;25:1337-1339.
9. Schwartz GL, Bailey KR, Mosley T, et al. Association of ambulatory blood pressure with ischemic brain. Hypertension. 2007;49:1215-1216,1228-1234.
10. Asayama K, Ohkubo T, Kikuya M, et al. Prediction of stroke by home "morning" versus "evening" blood pressure values. Hypertension. 2006;48:737-743.
11. Ishikawa J, Kario K, Hoshide S, et al. Determinants of self-measured pulse rate profile in medicated hypertensives: the Jichi Morning Surge-1 (JMS-1) study. Am J Hypert. 2005;18:958-965.
12. Nichols WW, O'Rourke MF. McDonald's Blood flow in arteries: theoretical, experimental and clinical principles. 3rd ed. London: Edward Arnold; 1990:pp 77-142, 216-269, 283-359, 398-437.
13. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225.
14. Pini R, Cavallini MC, Palmieri V, et al. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol. 2008;51(25):2432-2439.
15. Agabiti-Rosei E, Mancia G, O'Rourke MF, et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007;50:154-160.
16. Dahlof B, Severs PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9849):895-906.
17. Scuteri A, Tesauro M, Appolloni S, et al. Arterial stiffness as an independent predictor of longitudinal changes in cognitive function in the older individual. J of Hypertens. 2007;25:1035-1040.
18. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
19. Okin PM, Devereux RB, Harris KE, et al. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalisation for heart failure in hypertensive patients. Ann Intern Med. 2007;147:311-319.
20. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment in the prediction of major cardio-vascular events. JAMA. 2004;292(19):2343-2349.
21. Tocci G, Sciarretta S, Volpe M. Development of heart failure in recent hypertensive trials. J Hypertens. 2008;26(7):1477-1486.
22. European Society of Hypertension Committee. 2007 Guidelines for the Management of Arterial Hypertension. J Hypertension. 2007;25:1105-1187.
23. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
24. Ingelsson E, Bjorklund-Bodegard K, Lind L, et al. Diurnal blood pressure pattern and risk of congestive heart failure. JAMA. 2006;295:2859-2866.
25. Aksnes TA, Flaa A, Strand A, Kjeldsen SE. Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure. J Hypertens. 2007;25:15-23.
26. Wachtell K, Okin PM, Olsen MH, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death. Circulation. 2007;116:700-705.
27. Khan N, MsAlister FA. Re-examining the efficacy of beta blockers for the treatment of hypertension: a meta-analysisi. CMAJ. 2006;174(12):1737-42.
28. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
29. Zhang H, Thijs L, Staessen JA. Blood pressure lowering for primary and secondary prevention of stroke. Hypertension. 2006;48(2):187-195.
30. Brophy JM, Joseph L, Rouleau JL. Beta Blockers in congestive heart failure: a Bayesian meta-analysis. Ann Int Med. 2001;134(7):550-556.
31. Williams B. The year in hypertension. J Am Coll Cardiol. 2008;51:1802-1817.
32. Schocken DD, Benjamin EJ, Fonarow GC, et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008;117(19):2544-2565.
33. Tzemos N, Limm PO, Mac Donald TM. Nebivolol reverses endothelial dysfunction in essential hypertension. Circulation. 2001;104:511-514.
34. Messerli FH, Re RN. Do we need yet another blocker of the renin-angiotensin system? J Am Coll Cardiol. 2007;49(11):1164-1165.
35. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47(3):352-358.
36. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36(3):646-661.
37. Law MR, Wald MJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427-1435.
38. Neutel JM, Sica DA, Franklin SS. Hypertension control: still not there-how to select the right add-on therapy to reach goal blood pressures. J Clin Hypertens. 2007;9(11):889-896.
39. Yiannakopoulou ECh, Papadopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil. 2005;12(3):243-249.
40. Garg JP, Elliott WJ, Folker A, et al. Resistant hypertension revisited: a comparison of 2 university-based cohorts. Am J Hypert. 2005;18:619-626.
41. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: Diagnosis, evaluation and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for high blood pressure research. Hypertension. 2008;51:1403-1419.
42. Lane DA, Shah S, Beevers DG. Low dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertension. 2007;25:891-894.
43. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354(16):1687-1697.
44. Frank J. Managing hypertension using combination therapy. Am Fam Physician. 2008;77(9):1279-1286.
45. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4(6):393-404.